Example logo GIS 26

Global Innovation Summit 2026

6 May 2026 | Basel, Switzerland

Home
Register
Register
Register

PartnershipUpdated on 10 April 2026

SCOLI Portfolio — ScoliGEN & ScoliVIEW IVD tools for adolescent idiopathic scoliosis

James Webb

Chief Commercial Officer at EpiDisease SL

Valencia, Spain

About

EpiDisease is offering the first-ever precision diagnostic portfolio for Adolescent Idiopathic Scoliosis (AIS), combining a saliva-based genetic risk tool (ScoliGEN) with an AI-powered automated Cobb angle measurement platform (ScoliVIEW).

ScoliGEN is already commercially available as an LDT with 90% sensitivity, and ScoliVIEW has been peer-reviewed and published in The Spine Journal with an ICC of 0.97 across 484 radiographs from four tertiary hospitals.

https://epidisease.com/en/2025/03/05/circulating-mirnas-as-diagnostic-biomarkers-for-adolescent-idiopathic-scoliosis-2/

https://epidisease.com/en/2026/03/05/a-fully-autonomous-ai-system-for-accurate-and-reproducible-cobb-angle-measurement-in-adolescent-idiopathic-scoliosis-a-multicenter-study/

CE-IVD certification is expected in 2026, with FDA discussions to follow. We are looking for out-licensing partners, distribution agreements, and established commercial players in diagnostics or medical imaging to scale these products globally in a $1.7B TAM where no competitor currently exists.

Organisation

EpiDisease SL

SME

Valencia, Spain

Similar opportunities